Rilotumumab

Tax included
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research.
MedChemExpress 
HY-P99217

Data sheet

Size
Multiple sizes
Reactivity
c-Met/HGFR
Application
Cancer-Kinase/protease
CAS
872514-65-3